A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04

Enrolling by invitationOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

November 30, 2036

Study Completion Date

November 30, 2036

Conditions
Cystinosis
Interventions
OTHER

Safety and Efficacy Assessments

Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.

Trial Locations (1)

92037

University of California San Diego, La Jolla

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

Cystinosis Research Foundation

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Stephanie Cherqui

OTHER